Nuvalent, Inc. 4

Ron Squarer had 6,281 RSUs and options on 4,418 Nuvalent Class A shares cashed out for cash consideration in connection with the GlaxoSmithKline merger at $124.00 per share.

On July 15, 2026, in connection with the cash acquisition of Nuvalent, Inc. by GlaxoSmithKline at $124.00 per share, Ron Squarer had 6,281 time-based restricted stock units in Nuvalent Class A Common Stock cancelled and converted into a cash payment equal to the number of units times the $124.00 offer price, and also had a stock option covering 4,418 shares (with a $105.74 exercise price) cancelled and cashed out for the in-the-money value based on the same offer price. These transactions are purely deal-driven equity award conversions under the merger agreement rather than discretionary open-market trades, and leave Squarer with no remaining direct ownership of Nuvalent Class A Common Stock following the closing of the merger.

Filing Facts

CIK

1861560

Ticker

NUVL

Form

4

Source Type

fda

Accession

0001193125-26-305080

Alert Tier

6